Literature DB >> 15147459

Multiple sclerosis in Nord-Trøndelag County, Norway: a prevalence and incidence study.

O P Dahl1, J H Aarseth, K M Myhr, H Nyland, R Midgard.   

Abstract

OBJECTIVE: To calculate the prevalence and incidence of multiple sclerosis (MS) in Nord-Trøndelag County, Norway.
MATERIAL AND METHODS: The study comprised everyone diagnosed with MS according to the Poser criteria. On 1 January 2000 a total of 208 were identified: 130 women (62.5%) and 78 men (37.5%). We calculated the crude and age-adjusted annual incidence rates from 1974 to 1999.
RESULTS: The prevalence on 1 January 2000 was 163.6 of 100,000, 204.8 of 100,000 for women and 122.6 of 100,000 for men. The age-adjusted annual incidence increased from 3.9 to 5.6 per 100,000 from 1974 to 1999; women from 4.6 to 6.3 and men from 2.2 to 4.4. After 1984, the incidence among women increased most, peaking at 10.2 per 100,000 in 1984-88.
CONCLUSIONS: MS incidence is increasing in Nord-Trøndelag County. The prevalence is among the highest ever in Norway. Copyright Blackwell Munksgaard 2003

Entities:  

Mesh:

Year:  2004        PMID: 15147459     DOI: 10.1111/j.1600-0404.2004.00244.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  18 in total

1.  Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis.

Authors:  Julie Dahl; Kjell-Morten Myhr; Anne Kjersti Daltveit; Nils Erik Gilhus
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

2.  Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway.

Authors:  Margitta T Kampman; Jan Harald Aarseth; Nina Grytten; Espen Benjaminsen; Elisabeth Gulowsen Celius; Ole Petter Dahl; Trygve Holmøy; Kristin Løken-Amsrud; Rune Midgard; Kjell-Morten Myhr; Geir Risberg; Anita Vatne; Oivind Torkildsen
Journal:  J Neurol       Date:  2013-01-06       Impact factor: 4.849

3.  Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.

Authors:  A Alonso; S S Jick; M J Olek; M A Hernán
Journal:  J Neurol       Date:  2007-10-01       Impact factor: 4.849

Review 4.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases.

Authors:  Glinda S Cooper; Milele L K Bynum; Emily C Somers
Journal:  J Autoimmun       Date:  2009-10-09       Impact factor: 7.094

5.  Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway.

Authors:  Catherine Smestad; Leiv Sandvik; Trygve Holmoy; Hanne Flinstad Harbo; Elisabeth Gulawson Celius
Journal:  J Neurol       Date:  2007-12-20       Impact factor: 4.849

Review 6.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

7.  Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.

Authors:  Seyed Aidin Sajedi; Fahimeh Abdollahi
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

Review 8.  Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.

Authors:  N Grytten; Ø Torkildsen; K-M Myhr
Journal:  Acta Neurol Scand       Date:  2015       Impact factor: 3.209

Review 9.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

10.  Multiple sclerosis in the far north--incidence and prevalence in Nordland County, Norway, 1970-2010.

Authors:  Espen Benjaminsen; Johnny Olavsen; Merethe Karlberg; Karl B Alstadhaug
Journal:  BMC Neurol       Date:  2014-12-04       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.